LENZ Therapeutics, Inc. - 8-K Filing
LENZ Therapeutics reported Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales driven by approximately 25,000 paid prescriptions filled during the quarter and a cumulative 46,000 paid prescriptions since launch through March 31, 2026. The company also announced an exclusive distribution agreement with Lunatus for the Middle East, generating $0.2 million in upfront license revenue. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $LENZ